The AMBRA1 Knockout Jurkat Polyclonal Cells represent a CRISPR/Cas9-engineered polyclonal knockout population generated from the Jurkat T-lymphoblastoid cell line. These cells harbor a targeted disruption of the AMBRA1 gene, resulting in loss of functional AMBRA1 protein. As a heterogeneous polyclonal knockout pool, this model provides a robust tool for studying the collective cellular consequences of AMBRA1 ablation without the confounding effects of single-clone variability. AMBRA1 encodes an autophagy- and cell cycle-associated scaffold protein critical for the formation of the ULK1-BECN1-PIK3C3 autophagy initiation complex and for mediating cyclin D1 degradation via the DDB1-CUL4 E3 ubiquitin ligase pathway.
Jurkat cells are an immortalized human T lymphocyte cell line originally derived from the peripheral blood of a patient with acute lymphoblastic leukemia. They serve as a well-characterized model for investigating T cell receptor signaling, proliferation, apoptosis, and transformation mechanisms. The lymphoid origin of Jurkat cells renders them particularly relevant for hematological malignancy research, including leukemias and lymphomas. Their genetic tractability and responsiveness to diverse stimuli make them a versatile host for CRISPR-based gene knockout studies.
At the molecular level, AMBRA1 functions as a scaffolding platform that bridges the ULK1 kinase to the class III phosphatidylinositol 3-kinase complex comprising BECN1 and PIK3C3, thereby promoting autophagy initiation downstream of nutrient-sensing signals. mTORC1 inhibits this process under nutrient-rich conditions, while ULK1 activation under starvation triggers AMBRA1-mediated autophagosome nucleation. Separately, AMBRA1 acts as a substrate receptor for the DDB1-CUL4A E3 ligase, targeting cyclin D1 for ubiquitin-dependent degradation and linking autophagy to cell cycle progression. Interacting factors include ULK1, BECN1, PIK3C3, DDB1, CUL4A, and cyclin D1, and pathway components encompass the ATG14 and ATG5-ATG12 conjugation systems. Consequently, AMBRA1 integrates autophagy initiation with proteasomal control of the G1/S transition.
In the Jurkat T cell context, disruption of AMBRA1 is expected to impair autophagy flux and dysregulate cyclin D1 turnover, thereby impacting cell cycle progression, survival, and drug sensitivity. Given the established roles of autophagy in leukemia cell maintenance and chemoresistance, this knockout model permits dissection of AMBRA1-dependent mechanisms in leukemogenesis and therapy response. The interplay between autophagy and cell cycle regulation in lymphoid cells makes these polyclonal knockout cells a valuable platform for elucidating how AMBRA1 loss modulates T cell proliferation, apoptotic thresholds, and stress adaptation.
Key applications of the AMBRA1 Knockout Jurkat Polyclonal Cells include autophagy assays such as GFP-LC3 puncta quantification, LC3 and p62 immunoblotting, and flux measurements using lysosomal inhibitors. Cell cycle profiling by flow cytometry, cyclin D1 abundance analysis, and phospho-signaling readouts (e.g., ULK1 phosphorylation) are well-suited for evaluating the dual roles of AMBRA1. Co-immunoprecipitation and mass spectrometry can be employed to map protein interaction networks altered by AMBRA1 deficiency. Furthermore, these cells enable drug screening studies targeting autophagy or cell cycle regulators and serve as a model for T cell leukemia research. For additional technical details, please contact Ascent Research.
